bpc 157 and retatrutide Retatrutide: The Ultimate Guide to the Revolutionary Triple-Agonist Peptide Retatrutide 10mg — Triple Receptor

The peptide is not FDA-approved for any medical condition and is typically used as a research compound or through compounding pharmacies

Secondary endpoints included the proportion of participants achieving 5% and 10% body weight reduction, absolute weight change in kg, change in waist circumference, lipid parameters including total cholesterol, HDL, LDL, VLDL, triglycerides, and glycaemic variables such as HbA1c, fasting glucose, insulin, HOMA-IR, and -cell function

See more information here

Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats